Subscribe To
GH / 4 Undervalued Small-Cap Stocks to Buy | February 13, 2023
GH News
By The Motley Fool
October 11, 2023
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
Guardant Health's various products are all designed to help physicians and patients fight cancer. The company's revenue growth has been good, but its more_horizontal
By Zacks Investment Research
September 29, 2023
Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?
Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help th more_horizontal
By The Motley Fool
September 28, 2023
Why Guardant Health Stock Jumped 15% This Week
Analysts at both Bernstein and Piper Sandler had good things to say about Guardant Health this week. Shares of the precision oncology company had plun more_horizontal
By The Motley Fool
September 28, 2023
Why Guardant Health Stock Popped Again Today
Guardant Health stock has lost half its value over the past year. That's the bad news. more_horizontal
By Zacks Investment Research
August 22, 2023
Wall Street Analysts Believe Guardant Health (GH) Could Rally 42.09%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Guardant Health (GH). While the effectiveness of thi more_horizontal
By Seeking Alpha
August 3, 2023
Guardant Health, Inc. (GH) Q2 2023 Earnings Call Transcript
Guardant Health, Inc. (NASDAQ:GH ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy more_horizontal
By Zacks Investment Research
August 3, 2023
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss o more_horizontal
By Seeking Alpha
July 10, 2023
Guardant Health: A Growth Company Expanding Its Product Line Quickly
Guardant Health's share price has been volatile over the past year, but with strong clinical volume growth, the company presents an interesting invest more_horizontal